AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2015
Feb 2, 2015
33422_dirs_2015-02-02_7ad66c3a-da76-47ba-9c2a-b188565cbd46.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2015-01-29
Reporting Person: CALLICUTT JACK W (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-01-29 | Stock option (right to buy) | $3.45 | A | 26000 | Acquired | 2025-01-29 | Common stock (26000) | Direct |
Footnotes
F1: The options vest as follows: 25% immediately, and the remaining 75% in equal installments on a monthly basis over a period of three years.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21